Evidence map›Paper›PMID 35654576›Full record

ReviewEndocrinology and metabolism (Seoul, Korea)2022

Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer.

Siva Swapna Kasarla, Vannuruswamy Garikapati, Yashwant Kumar, Sujatha Dodoala

Open access · diamondAbstract readReview
In one paragraph

Review in Endocrinology and metabolism (Seoul, Korea), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Massively parallel reporter assays forbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Bile acids as therapeutic agents.Frontiers in pharmacology · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Research progress regardingZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Siva Swapna KasarlaBiomarker Discovery Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
Vannuruswamy GarikapatiInstitute of Inorganic and Analytical Chemistry, Justus Liebig University Giessen, Giessen, Germany.
Yashwant KumarBiomarker Discovery Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
Sujatha DodoalaInstitute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati, India.
Translational Health Science and Technology Institute · INJustus-Liebig-Universität Gießen · DESri Padmavati Mahila Visvavidyalayam · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past few decades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is highly questionable in disease states due to flexible alterations in the enzymes responsible for their metabolism. For instance, CYP3A4 plays a crucial role in the biotransformation of vitamin D and other drug substances. Food-drug and/or drug-drug interactions, the disease state, genetic polymorphism, age, sex, diet, and environmental factors all influence CYP3A4 activity. Genetic polymorphisms in CYP450-encoding genes have received considerable attention in the past few decades due to their extensive impact on the pharmacokinetic and dynamic properties of drugs and endogenous substances. In this review, we focused on CYP3A4 polymorphisms and their interplay with vitamin D metabolism and summarized the role of vitamin D in calcium homeostasis, bone diseases, diabetes, cancer, other diseases, and drug substances. We also reviewed clinical observations pertaining to CYP3A4 polymorphisms among the aforementioned disease conditions. In addition, we highlighted the future perspectives of studying the pharmacogenetics of CYP3A4, which may have potential clinical significance for developing novel diagnostic genetic markers that will ascertain disease risk and progression.

Indexed as

Endocrine System DiseasesNeoplasmsCytochrome P-450 CYP3AHumansPharmacogeneticsPolymorphism, GeneticVitamin DCYP3A4 protein, humanCytochrome P-450 CYP3AVitamin DBone diseasesCOVID-19Cytochrome P-450 CYP3ADiabetes mellitusImmune systemNeoplasmsVitamin D

Identifiers

PMID35654576
PMCPMC9262690
OpenAlexW4281785688

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.